← Back to Search

Non-invasive Brain Stimulation

Mag Stim for Lou Gehrig's Disease

N/A
Waitlist Available
Research Sponsored by Hospital for Special Surgery, New York
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18, men or woman
Diagnosis of upper motor neuron predominant ALS, which also includes patients with primary lateral sclerosis (PLS), as defined as only upper motor neuron features in at least 2 body segments.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 0 to end of the study, an average of 5 months
Awards & highlights

Study Summary

This trial will help researchers learn if a certain type of brain stimulation can help reduce spasticity and improve quality of life for people with MND.

Eligible Conditions
  • Lou Gehrig's Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 0 to end of the study, an average of 5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 0 to end of the study, an average of 5 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
safety of rTMS in subjects with PLS/UMN/MND. Number of participants with treatment related AE's will be measured with stringent stopping rules and reported. We hypothesize that no serious treatment related adverse event.
Secondary outcome measures
To evaluate efficacy of rTMS using a modified FDA approved protocol in research subjects with PLS and UMN/MND.

Trial Design

1Treatment groups
Experimental Treatment
Group I: rTMS armExperimental Treatment1 Intervention
Each patient's participation will last a maximum of 12 weeks and involves 2 sessions of neurophysiological testing (TMS) sessions and 15 neurophysiological treatment sessions (rTMS). Patients will have a neurophysiological testing session (TMS) at the screening visit (week 0). Patients will then return for 15 neurophysiological treatment sessions (rTMS) within 14 days of screening. Patients must complete three neurophysiological treatment sessions (rTMS) during weeks 1, 2, 3, 4 and 5. The second neurophysiological testing session will be done at the final visit (week 5). Follow-up visits will be scheduled at weeks 7 and 10 (+/- 3 days). That is, the follow-up visits will occur two and five weeks after the final rTMS session which occurs on day 15.

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkLead Sponsor
243 Previous Clinical Trials
59,361 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
rTMS in Treatment of Spasticity
2018. "rTMS in Treatment of Spasticity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04054141.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top